agendia mammaprint microarray Search Results


genomic testing mammaprint  (Agendia BV)
90
Agendia BV genomic testing mammaprint
Genomic Testing Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/pmc07101250-237-21-22?v=Agendia+BV
Average 90 stars, based on 1 article reviews
genomic testing mammaprint - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mammaprint (mp) microarray-based genomic tests  (Agendia BV)
90
Agendia BV mammaprint (mp) microarray-based genomic tests
Mammaprint (Mp) Microarray Based Genomic Tests, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/10__1093_slash_annonc_slash_mdz257__019-105-20-14?v=Agendia+BV
Average 90 stars, based on 1 article reviews
mammaprint (mp) microarray-based genomic tests - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mammaprint (mp) microarray  (Agendia BV)
90
Agendia BV mammaprint (mp) microarray
<t>MammaPrint</t> (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
Mammaprint (Mp) Microarray, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/pmc06742807-134-0-6?v=Agendia+BV
Average 90 stars, based on 1 article reviews
mammaprint (mp) microarray - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers  (Agendia BV)
90
Agendia BV mammaprint dna microarray-based test for prognosis of her2þ early breast cancers
<t>MammaPrint</t> (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/pm20346697-199-21-13?v=Agendia+BV
Average 90 stars, based on 1 article reviews
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
customized agendia mammaprint 8-pack microarray  (Agendia BV)
90
Agendia BV customized agendia mammaprint 8-pack microarray
<t>MammaPrint</t> (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
Customized Agendia Mammaprint 8 Pack Microarray, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/pm20383789-56-10-11?v=Agendia+BV
Average 90 stars, based on 1 article reviews
customized agendia mammaprint 8-pack microarray - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
gene expression microarrays mammaprint  (Agendia BV)
90
Agendia BV gene expression microarrays mammaprint
<t>MammaPrint</t> (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
Gene Expression Microarrays Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/pm19961955-162-3-37?v=Agendia+BV
Average 90 stars, based on 1 article reviews
gene expression microarrays mammaprint - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mammaprints microarray  (Agendia BV)
90
Agendia BV mammaprints microarray
<t>MammaPrint</t> (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
Mammaprints Microarray, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/10__1097_slash_pap__0000000000000128-127-24-57?v=Agendia+BV
Average 90 stars, based on 1 article reviews
mammaprints microarray - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites.

Techniques: Microarray, Comparison

Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

Article Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites.

Techniques: Comparison, Microarray

Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 <xref ref-type= ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D )." width="100%" height="100%">

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

Article Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites.

Techniques: Comparison, Microarray

MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites.

Techniques: Comparison, Microarray